scholarly journals Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group

2021 ◽  
Vol 125 (7) ◽  
pp. 911-919
Author(s):  
Thibaud Koessler ◽  
Maria Alsina ◽  
Dirk Arnold ◽  
Irit Ben-Aharon ◽  
Manfred P. Lutz ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Routine Clinical Practice ◽  
Large Trial ◽  
Advanced Hepatocellular Carcinoma ◽  
Tract Cancer ◽  
Cancer Group ◽  
Gastrointestinal Tract Cancer ◽  
Early Phase Trials ◽  
Future Treatments

AbstractLast year the field of immunotherapy was finally introduced to GI oncology, with several changes in clinical practice such as advanced hepatocellular carcinoma or metastatic colorectal MSI-H. At the virtual ASCO-GI symposium 2021, several large trial results have been reported, some leading to a change of practice. Furthermore, during ASCO-GI 2021, results from early phase trials have been presented, some with potential important implications for future treatments. We provide here an overview of these important results and their integration into routine clinical practice.

The EORTC Gastrointestinal Tract Cancer Group

2002 ◽  
Vol 38 ◽  
pp. 65-70 ◽  
Author(s):  
Ö Anak ◽  
E Van Cutsem ◽  
B Nordlinger
Keyword(s):  
Gastrointestinal Tract ◽  
Tract Cancer ◽  
Cancer Group ◽  
Gastrointestinal Tract Cancer

scholarly journals Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice

Hepatology ◽  
2018 ◽  
Vol 67 (5) ◽  
pp. 1784-1796 ◽  
Author(s):  
Edoardo Giovanni Giannini ◽  
Laura Bucci ◽  
Francesca Garuti ◽  
Matteo Brunacci ◽  
Barbara Lenzi ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Advanced Hepatocellular Carcinoma ◽  
Personalized Management

Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

2021 ◽  
Vol 1 (2) ◽  
pp. 83-88
Author(s):  
TEIJI KUZUYA ◽  
NAOTO KAWABE ◽  
SENJU HASHIMOTO ◽  
RYOJI MIYAHARA ◽  
TAKUJI NAKANO ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Practice ◽  
Adverse Events ◽  
Response Rate ◽  
Objective Response ◽  
Evaluation Criteria ◽  
Advanced Hepatocellular Carcinoma ◽  
Response Evaluation ◽  
Modified Recist ◽  
Grade 3

Background/Aim: The aim of this study was to investigate the outcomes of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma (HCC), including those with disease refractory to lenvatinib, in clinical practice. Patients and Methods: Of 34 patients treated with atezolizumab plus bevacizumab, a total of 23, including 16 with lenvatinib failure, were enrolled in this retrospective study. The adverse events, changes in liver function and antitumor responses at 6 weeks after starting therapy were evaluated. Results: The incidence of grade 3 adverse events was low, at 13.0%. Albumin–bilirubin scores did not worsen at 3 and 6 weeks compared to baseline. The objective response rate and disease control rate at 6 weeks were 17.4% and 78.3% according to Response Evaluation Criteria in Solid Tumors (RECIST), and 30.4% and 78.3% according to modified RECIST, respectively. Conclusion: Our results suggest that atezolizumab plus bevacizumab might have potential therapeutic safety and efficacy in patients with advanced HCC, including those with disease refractory to lenvatinib. Further studies are needed to confirm the outcomes of atezolizumab plus bevacizumab after lenvatinib failure.

Sign in / Sign up

Export Citation Format

Share Document